Skip to main content

Table 2 Virological response in the study group

From: NS34A resistance-associated substitutions in chronic hepatitis C in Upper Egypt and regression of liver fibrosis after direct-acting antiviral therapy

Item F3, F4 F0–F2 Total
Response:
• Patients who achieved SVR12 92.9% (26/28) 100% (31/31) 57 (96.6%)
• Patients who did not achieve SVR12 7.1% (2/28) 0 (0%) 2 (3.4%)
p value 0.001* NA 0.001*
  1. Total number = 59 patients
  2. NA not applicable, SVR12 sustained virological response with HCV RNA negative at 12 weeks after the end of therapy
  3. * Statistically significant